{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:20:27Z","timestamp":1786998027445,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virus Research"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.virusres.2023.199176","type":"journal-article","created":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T17:33:10Z","timestamp":1690047190000},"page":"199176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Construction of Fosmid-based SARS-CoV-2 replicons for antiviral drug screening and replication analyses in biosafety level 2 facilities"],"prefix":"10.1016","volume":"334","author":[{"given":"Shunta","family":"Takazawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Kotaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satsuki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Utsubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5525-9915","authenticated-orcid":false,"given":"Masanori","family":"Kameoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.virusres.2023.199176_bib0001","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.3390\/jcm11133838","article-title":"Current effective therapeutics in management of COVID-19","volume":"11","author":"Atluri","year":"2022","journal-title":"J. Clin. Med."},{"issue":"19","key":"10.1016\/j.virusres.2023.199176_bib0002","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virusres.2023.199176_bib0003","unstructured":"Centers for Disease Control and Prevention (CDC), 2022. Overview of COVID-19 vaccines https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/different-vaccines\/overview-COVID-19-vaccines.html (accessed 20 January 2023)."},{"key":"10.1016\/j.virusres.2023.199176_bib0004","unstructured":"Centers for Disease Control and Prevention (CDC), 2021. Interim laboratory biosafety guidelines for handling and processing specimens associated with coronavirus disease 2019 (COVID-19). https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/lab\/lab-biosafety-guidelines.html (accessed 30 June 2023)."},{"issue":"10223","key":"10.1016\/j.virusres.2023.199176_bib0005","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.virusres.2023.199176_bib0006","doi-asserted-by":"crossref","first-page":"6078","DOI":"10.1002\/jmv.28057","article-title":"Production of single-cycle infectious SARS-CoV-2 through a trans-complemented replicon","volume":"94","author":"Cheung","year":"2022","journal-title":"J. Med. Virol."},{"issue":"6492","key":"10.1016\/j.virusres.2023.199176_bib0007","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.abb7498","article-title":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus","volume":"368","author":"Gao","year":"2020","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.virusres.2023.199176_bib0008","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2025866118","article-title":"Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing","volume":"118","author":"He","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"678","key":"10.1016\/j.virusres.2023.199176_bib0009","doi-asserted-by":"crossref","first-page":"eabq7360","DOI":"10.1126\/scitranslmed.abq7360","article-title":"SARS-CoV-2 3CL(pro) mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376","volume":"15","author":"Heilmann","year":"2023","journal-title":"Sci. Transl. Med."},{"issue":"10223","key":"10.1016\/j.virusres.2023.199176_bib0010","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.virusres.2023.199176_bib0011","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s12250-021-00385-9","article-title":"A convenient and biosafe replicon with accessory genes of SARS-CoV-2 and its potential application in antiviral drug discovery","volume":"36","author":"Jin","year":"2021","journal-title":"Virol. Sin."},{"issue":"1","key":"10.1016\/j.virusres.2023.199176_bib0012","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1038\/s41598-021-82055-0","article-title":"A PCR amplicon-based SARS-CoV-2 replicon for antiviral evaluation","volume":"11","author":"Kotaki","year":"2021","journal-title":"Sci. Rep."},{"issue":"10325","key":"10.1016\/j.virusres.2023.199176_bib0013","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0140-6736(22)00090-3","article-title":"Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose","volume":"399","author":"Kuhlmann","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.virusres.2023.199176_bib0014","doi-asserted-by":"crossref","DOI":"10.1128\/mmbr.00026-21","article-title":"Molecular virology of SARS-CoV-2 and related coronaviruses","volume":"86","author":"Kung","year":"2022","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.virusres.2023.199176_bib0015","first-page":"1","article-title":"Interferon antagonists encoded by SARS-CoV-2 at a glance","author":"Lee","year":"2022","journal-title":"Med. Microbiol. Immunol."},{"issue":"1","key":"10.1016\/j.virusres.2023.199176_bib0016","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1038\/s41467-020-17665-9","article-title":"Activation and evasion of type I interferon responses by SARS-CoV-2","volume":"11","author":"Lei","year":"2020","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.virusres.2023.199176_bib0017","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.02216-21","article-title":"Stable cell clones harboring self-replicating SARS-CoV-2 RNAs for drug screen","volume":"96","author":"Liu","year":"2022","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.virusres.2023.199176_bib0018","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01837-21","article-title":"Development of a single-cycle infectious SARS-CoV-2 virus replicon particle system for use in biosafety level 2 laboratories","volume":"96","author":"Malicoat","year":"2022","journal-title":"J. Virol."},{"issue":"18","key":"10.1016\/j.virusres.2023.199176_bib0019","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00687-21","article-title":"Construction of a noninfectious SARS-CoV-2 replicon for antiviral-drug testing and gene function studies","volume":"95","author":"Nguyen","year":"2021","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.virusres.2023.199176_bib0020","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00097-21","article-title":"Overcoming culture restriction for SARS-CoV-2 in human cells facilitates the screening of compounds inhibiting viral replication","volume":"65","author":"Ramirez","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.virusres.2023.199176_bib0021","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/s41423-020-0485-9","article-title":"The ORF3a protein of SARS-CoV-2 induces apoptosis in cells","volume":"17","author":"Ren","year":"2020","journal-title":"Cell Mol. Immunol."},{"issue":"17","key":"10.1016\/j.virusres.2023.199176_bib0022","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00402-21","article-title":"Contribution of SARS-CoV-2 accessory proteins to viral pathogenicity in K18 human ACE2 transgenic mice","volume":"95","author":"Silvas","year":"2021","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.virusres.2023.199176_bib0023","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMc2119407","article-title":"Efficacy of antibodies and antiviral drugs against Covid-19 Omicron variant","volume":"386","author":"Takashita","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virusres.2023.199176_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105268","article-title":"Establishment of a stable SARS-CoV-2 replicon system for application in high-throughput screening","volume":"199","author":"Tanaka","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virusres.2023.199176_bib0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-1-4939-6481-9_2","article-title":"Self-replicating RNA","volume":"1499","author":"Tews","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.virusres.2023.199176_bib0026","unstructured":"The Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU), 2023. COVID-19 Dashboard. https:\/\/coronavirus.jhu.edu\/map.html (Accessed 20 January 2023)."},{"issue":"3","key":"10.1016\/j.virusres.2023.199176_bib0027","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.virusres.2023.199176_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108234","article-title":"Evasion of type I interferon by SARS-CoV-2","volume":"33","author":"Xia","year":"2020","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.virusres.2023.199176_bib0029","doi-asserted-by":"crossref","DOI":"10.1099\/jgv.0.001583","article-title":"SARS-CoV-2 replicon for high-throughput antiviral screening","volume":"102","author":"Zhang","year":"2021","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virusres.2023.199176_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104974","article-title":"A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2","volume":"185","author":"Zhang","year":"2021","journal-title":"Antivir. Res."}],"container-title":["Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170223001387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170223001387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T14:22:46Z","timestamp":1759155766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168170223001387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":30,"alternative-id":["S0168170223001387"],"URL":"https:\/\/doi.org\/10.1016\/j.virusres.2023.199176","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.02.15.528742","asserted-by":"object"}]},"ISSN":["0168-1702"],"issn-type":[{"value":"0168-1702","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Construction of Fosmid-based SARS-CoV-2 replicons for antiviral drug screening and replication analyses in biosafety level 2 facilities","name":"articletitle","label":"Article Title"},{"value":"Virus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virusres.2023.199176","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"199176"}}